Cargando…

Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC

BACKGROUND: To investigate the potential impact of fractionation regimes and overall treatment time (OTT) on lymphopenia during definitive radiotherapy (RT) and its associations with patient outcomes in non-small cell lung cancer (NSCLC). METHODS: Subjects consisted of 115 patients who had received...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Qianqian, Chen, Gang, Ye, Luxi, Shi, Shiming, Du, Shisuo, Zeng, Zhaochong, He, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537222/ https://www.ncbi.nlm.nih.gov/pubmed/31133034 http://dx.doi.org/10.1186/s13014-019-1287-z

Ejemplares similares

Clinical outcomes of stereotactic body radiotherapy for de novo pulmonary tumors in patients with completely resected early stage non-small cell lung cancer
por: Zhao, Qianqian, et al.
Publicado: (2018)

Outcomes of Image-Guided Moderately Hypofractionated Radiotherapy for Stage III Non-Small-Cell Lung Cancer
por: Zhang, Yang, et al.
Publicado: (2021)

Emphysema quantification on computed tomography and its value in predicting radiation pneumonitis in lung cancer treated by stereotactic body radiotherapy
por: Ye, Luxi, et al.
Publicado: (2019)

Shortened Radiation Time Promotes Recovery From Radiation-induced Lymphopenia in Early-Stage Non-small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
por: Zhao, Qianqian, et al.
Publicado: (2022)

A randomized trial of conventional fraction versus hypofraction radiotherapy for bone metastases from hepatocellular carcinoma
por: He, Jian, et al.
Publicado: (2019)

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
por: Denault, Marie-Helene, et al.
Publicado: (2023)

Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab
por: Nindra, Udit, et al.
Publicado: (2022)

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
por: Agbarya, Abed, et al.
Publicado: (2022)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2023)

Comparison of long-term outcomes of stereotactic body radiotherapy (SBRT) via Helical tomotherapy for early-stage lung cancer with or without pathological proof
por: Fan, Shaonan, et al.
Publicado: (2023)

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
por: Martel-Lafay, Isabelle, et al.
Publicado: (2021)

Higher serum sPD-L1 levels after radiotherapy indicate poor outcome in hepatocellular carcinoma patients
por: Zhang, Yang, et al.
Publicado: (2022)

Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2022)

Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
por: Remon, Jordi, et al.
Publicado: (2022)

Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial
por: Ko, Jenny J., et al.
Publicado: (2023)

Gross Tumor Volume Segmentation for Stage III NSCLC Radiotherapy Using 3D ResSE-Unet
por: Yu, Xinhao, et al.
Publicado: (2022)

Minimum absolute lymphocyte counts during radiation are associated with a worse prognosis in patients with unresectable hepatocellular carcinoma
por: Zhao, Qianqian, et al.
Publicado: (2016)

Development and validation of a random forest model for predicting radiation pneumonitis in lung cancer patients receiving moderately hypofractionated radiotherapy: a retrospective cohort study
por: Zhang, Yang, et al.
Publicado: (2022)

Impacts of post‐radiotherapy lymphocyte count on progression‐free and overall survival in patients with stage III lung cancer
por: Matiello, Juliana, et al.
Publicado: (2020)

Treatment Patterns for Patients With Unresected Stage III NSCLC: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
por: Shang, Shijie, et al.
Publicado: (2022)

Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and (18)F-FDG PET/CT for radiotherapy target volume definition
por: Guberina, Maja, et al.
Publicado: (2021)

Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy
por: Iseli, Thomas, et al.
Publicado: (2020)

Foreword to ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

Summary of ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china
por: Jiang, Xiaotong, et al.
Publicado: (2022)

Competing Risk Analysis of Outcomes of Unresectable Pancreatic Cancer Patients Undergoing Definitive Radiotherapy
por: Chen, Yi-Lun, et al.
Publicado: (2022)

Peripheral Lymphocyte Counts and Lymphocyte-Related Inflammation Indicators During Radiotherapy for Pelvic Malignancies: Temporal Characterization and Dosimetric Predictors
por: Xiang, Xiaoyong, et al.
Publicado: (2022)

A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China
por: Li, Wei, et al.
Publicado: (2023)

Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling
por: Li, Zongjuan, et al.
Publicado: (2022)

Induction Therapy Followed by Surgery for Unresectable Thymic Epithelial Tumours
por: Wang, Shuai, et al.
Publicado: (2022)

Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I‐II or unresected stage III pancreatic cancer
por: Ma, Sung J., et al.
Publicado: (2019)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC
por: Philippe, Jagoda, et al.
Publicado: (2021)

Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer
por: Kerner, Gerald SMA, et al.
Publicado: (2014)

Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective
por: Dunlop, Will, et al.
Publicado: (2021)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

Effect of Lymph Node Count on Pathological Stage III Rectal Cancer with Preoperative Radiotherapy
por: Li, Qingguo, et al.
Publicado: (2015)

Correction to: Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC
por: Jagoda, Philippe, et al.
Publicado: (2021)

Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non‐small‐cell lung cancer after definitive chemoradiotherapy
por: Sakaguchi, Tadashi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_drai5pr98ei1k18pahartl2i4n